活动性眼弓形虫病临床特征及预后分析

doi:10.6040/j.issn.1673-3770.0.2024.635

摘要/Abstract

摘要： 目的回顾性分析活动性眼弓形虫病的临床特征及其治疗预后。方法收集经眼内液及血清学检测被确诊为眼弓形虫病的患者的临床资料进行回顾性分析。结果 12例(13眼)中男2例(3眼)、女10例(10眼),首诊年龄17~73(37.4±16.7)岁。随访6~32个月,中位数8个月。首诊时伴眼前节炎症12眼(92.3%),其中3眼(23.1%)伴虹膜后粘连;4眼(30.8%)继发高眼压;所有患者的玻璃体均有不同程度炎性混浊,其中3眼(23.1%)玻璃体重度混浊,导致眼底几乎完全窥不见。眼底表现具有多样性,10眼(76.9%)可见脉络膜视网膜坏死性病灶,其中3眼(23.1%)坏死病灶累及黄斑区,病灶位于黄斑外伴发黄斑水肿2眼;5眼(38.5%)视盘水肿,其中2眼视盘旁黄白色病灶约1/2PD;活动性病灶旁有色素性视网膜脉络膜瘢痕者6眼(46.2%)。8眼(61.5%)首次就诊后进行眼内液寄生虫检测确诊;其余4例(5眼,38.5%)首诊漏诊,其中2例(2眼)为视神经水肿显著伴视盘旁局部病灶者,1例(1眼)坏死病灶范围较大,几乎累及整个鼻上象限,1例(2眼)玻璃体重度浑浊无法窥及眼底,这4例患者自初诊至采集眼内液检测确诊间隔时间分别为0.87、7.77、0.45及1个月。确诊后的患者均接受了全身及局部抗生素和糖皮质激素的综合治疗,其中3例患者接受了玻璃体切除手术。随访期间,1例患者病情持续恶化,另1例在治疗后稳定2年病情复发并加重。其余11眼经治疗后病情好转并保持稳定,末次就诊时logMAR BCVA较初诊时有所改善。其中继发黄斑前膜2眼、继发玻璃体黄斑牵拉1眼。结论弓形虫眼病临床表现及病变类型复杂多样,视网膜脉络膜坏死性炎症病灶位置及范围差异较大,其中视盘旁小病灶因视盘高度水肿容易被临床忽视,坏死病灶范围广泛者也具有迷惑性;此外,炎症易累及玻璃体、视神经及黄斑。患者预后与病灶严重程度密切相关。临床需结合患者病史、症状、影像学、实验室检查,对于可疑患者应及时进行眼内液及血清弓形虫抗体或DNA检测,以期及时确诊及治疗,改善预后。

关键词: 眼弓形虫病, 临床体征, 葡萄膜炎, 眼内液检测, 预后

Abstract: Objective To retrospectively analyze the clinical characteristics and treatment outcomes of active ocular toxoplasmosis. Methods Clinical data were retrospectively analyzed from patients diagnosed with ocular toxoplasmosis. The diagnosis was confirmed through intraocular fluid and serological testing. Results The study included 12 cases(13 eyes), comprising 2 males(3 eyes)and 10 females(10 eyes). The age at initial diagnosis ranged from 17 to 73, with a mean of 37.4±16.7 years. The follow-up period ranged from 6 to 32 months, with a median duration of 8 months. At the initial visit, 12 eyes(92.3%)showed anterior segment inflammation, including 3 eyes(23.1%)with posterior synechiae. 4 eyes(30.8%)developed secondary ocular hypertension. All patients exhibited varying degrees of vitreous inflammatory haze, with 3 eyes(23.1%)showing severe vitreous opacity that nearly completely obscured the fundus view. Fundus manifestations were diverse. 10 eyes(76.9%)displayed necrotizing chorioretinal lesions, including 3 eyes(23.1%)with macular involvement. 2 eyes exhibited macular edema alongside extramacular lesions. 5 eyes(38.5%)had optic disc edema, among which 2 eyes showed yellowish-white peripapillary lesions approximately half a disc diameter in size. 6 eyes(46.2%)presented with pigmented chorioretinal scars adjacent to active lesions. Diagnosis was confirmed by intraocular fluid testing in 8 eyes(61.5%)during their first visit. However, 4 cases(5 eyes, 38.5%)were initially missed. Among them, 2 cases(2 eyes)showed significant optic nerve edema with peripapillary lesions; 1 case(1 eye)had a large necrotizing lesion involving nearly the entire superonasal quadrant; and 1 case(2 eyes)had severe vitreous opacity that prevented fundus examination. The intervals from initial visit to confirmatory intraocular fluid testing for these 4 cases were 0.87, 7.77, 0.45, and 1.0 months, respectively. All diagnosed patients received systemic and topical antibiotic, as well as corticosteroid therapy, with 3 cases undergoing vitrectomy. During follow-up, 1 patient experienced continuous deterioration, and another had recurrence with worsening after 2 years of stability. The remaining 11 eyes showed improvement and remained stable, with better log MAR BCVA at the last visit compared to initial presentation. Two eyes developed epiretinal membranes, and 1 eye developed vitreomacular traction. Conclusion Ocular toxoplasmosis presents complex and varied clinical manifestations. Necrotizing chorioretinal inflammatory lesions differ greatly in location and size. Specifically, small peripapillary lesions may be overlooked because of severe optic disc edema, while extensive necrotic lesions might cause diagnostic confusion. Moreover, inflammation frequently affects the vitreous, optic nerve, and macula. Patient prognosis largely depends on lesion severity. Clinical diagnosis should comprehensively consider patient history, symptoms, imaging, and laboratory tests. In suspected cases, timely testing of intraocular fluid and serum for Toxoplasma antibodies or DNA is essential. This approach facilitates early diagnosis and treatment, thereby improving patient outcomes.

Key words: Ocular toxoplasmosis, Clinical signs, Uveitis, Intraocular fluid testing, Prognosis

中图分类号:

R773.9

缪红利,张妍春,郝琳娜,唐乐,何英楠. 活动性眼弓形虫病临床特征及预后分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 82-89.

MIAO Hongli, ZHANG Yanchun, HAO Linna, TANG Le, HE Yingnan. Clinical features and prognostic analysis of active ocular toxoplasmosis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 82-89.

参考文献 36

[1]	Goh EJH, Putera I, La Distia Nora R, et al. Ocular toxoplasmosis[J]. Ocul Immunol Inflamm, 2022, 31(7): 1342-1361. doi: 10.1080/09273948.2022.2117705
[2]	Karami M, Gorgani-Firouzjaee T, Rostami-Mansour S, et al. Prevalence of ocular toxoplasmosis in the general population and uveitis patients: a systematic review and meta-analysis[J]. Ocul Immunol Inflamm, 2024, 32(6): 1003-1016. doi: 10.1080/09273948.2023.2190801
[3]	Delair E, Latkany P, Noble AG, et al. Clinical manifestations of ocular toxoplasmosis[J]. Ocul Immunol Inflamm, 2011, 19(2): 91-102. doi: 10.3109/09273948.2011.564068
[4]	Miyagaki M, Zong Y, Yang MM, et al. Ocular toxoplasmosis: advances in Toxoplasma gondii biology, clinical manifestations, diagnostics, and therapy[J]. Pathogens, 2024, 13(10): 898. doi: 10.3390/pathogens13100898
[5]	Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection?[J]. Br J Ophthalmol, 2000, 84(2): 224-226. doi: 10.1136/bjo.84.2.224
[6]	Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis[J]. Jpn J Ophthalmol, 2004, 48(4): 386-391. doi: 10.1007/s10384-003-0069-0
[7]	Bosch-Driessen LEH, Berendschot TTJM, Ongkosuwito JV, et al. Ocular toxoplasmosis: clinical features and prognosis of 154 patients[J]. Ophthalmology, 2002, 109(5): 869-878. doi: 10.1016/s0161-6420(02)00990-9
[8]	Ozgonul C, Besirli CG. Recent developments in the diagnosis and treatment of ocular toxoplasmosis[J]. Ophthalmic Res, 2017, 57(1): 1-12. doi: 10.1159/000449169
[9]	Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis[J]. Arch Ophthalmol, 2011, 129(5): 545-553. doi: 10.1001/archophthalmol.2010.339
[10]	Smith JR, Ashander LM, Arruda SL, et al. Pathogenesis of ocular toxoplasmosis[J]. Prog Retin Eye Res, 2021, 81: 100882. doi: 10.1016/j.preteyeres.2020.100882
[11]	Dubey JP.Toxoplasmosis of animals and humans[M]. 2rd ed. Boca Raton: CRC Press, 2009:1-118.
[12]	Pleyer U, Schlüter D, Mönz M. Ocular toxoplasmosis: recent aspects of pathophysiology and clinical implications[J]. Ophthalmic Res, 2014, 52(3): 116-123. doi: 10.1159/000363141
[13]	Vasconcelos-Santos DV, Dodds EM, Oréfice F. Review for disease of the year: differential diagnosis of ocular toxoplasmosis[J]. Ocul Immunol Inflamm, 2011, 19(3): 171-179. doi: 10.3109/09273948.2011.581407
[14]	Ben-Harari RR, Goodwin E, Casoy J. Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review[J]. Drugs R D, 2017, 17(4): 523-544. doi: 10.1007/s40268-017-0206-8
[15]	Ham DW, Jung BK, Shin JH, et al. Clinical characteristics of toxoplasmosis patients in Korea: a retrospective study using health insurance review and assessment service data and electronic medical records[J]. Parasites Hosts Dis, 2024, 62(4): 424-437. doi: 10.3347/PHD.24001
[16]	Holland GN. Ocular toxoplasmosis: a global reassessment. part II: disease manifestations and management[J]. Am J Ophthalmol, 2004, 137(1): 1-17.
[17]	Delair E, Latkany P, Noble AG, et al. Clinical manifestations of ocular toxoplasmosis[J]. Ocul Immunol Inflamm, 2011, 19(2): 91-102. doi: 10.3109/09273948.2011.564068
[18]	Pichi F, Veronese C, Lembo A, et al. New appraisals of kyrieleis plaques: a multimodal imaging study[J]. Br J Ophthalmol, 2017, 101(3): 316-321. doi: 10.1136/bjophthalmol-2015-308246
[19]	Kalogeropoulos D, Sakkas H, Mohammed B, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches[J]. Int Ophthalmol, 2022, 42(1): 295-321. doi: 10.1007/s10792-021-01994-9
[20]	Belk K, Connolly MP, Schlesinger L, et al. Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the vizient health systems data from 2011 to 2017[J]. Pathog Glob Health, 2018, 112(8): 428-437. doi: 10.1080/20477724.2018.1552644
[21]	Fish RH, Hoskins JC, Kline LB. Toxoplasmosis neuroretinitis[J]. Ophthalmology, 1993, 100(8): 1177-1182. doi: 10.1016/S0161-6420(13)31511-5
[22]	Bokharaei-Salim F, Esteghamati A, Khanaliha K, et al. Evaluation of a PCR assay for diagnosis of toxoplasmosis in serum and peripheral blood mononuclear cell among HIV/AIDS patients[J]. J Parasit Dis, 2020, 44(1): 159-165. doi: 10.1007/s12639-019-01176-6
[23]	Maenz M, Schlüter D, Liesenfeld O, et al. Ocular toxoplasmosis past, present and new aspects of an old disease[J]. Prog Retin Eye Res, 2014, 39: 77-106. doi: 10.1016/j.preteyeres.2013.12.005
[24]	陶勇, 石燕红. 合理使用眼内液检测,辅助眼底疾病的精准诊疗[J]. 中华眼底病杂志, 2021, 37(7): 497-502. doi: 10.3760/cma.j.cn511434-20210315-00134 TAO Yong, SHI Yanhong. Proper use of examination of intraocular fluid to assist precise diagnosis and treatment of vitreoretinaldiseases[J]. Chin J Ocul Fundus Dis, 2021, 37(7): 497-502. doi: 10.3760/cma.j.cn511434-20210315-00134
[25]	Marcolino PT, Silva DA, Leser PG, et al. Molecular markers in acute and chronic phases of human toxoplasmosis: determination of immunoglobulin G avidity by Western blotting[J]. Clin Diagn Lab Immunol, 2000, 7(3): 384-389. doi: 10.1128/CDLI.7.3.384-389.2000
[26]	Bourdin C, Busse A, Kouamou E, et al. PCR-based detection of Toxoplasma gondii DNA in blood and ocular samples for diagnosis of ocular toxoplasmosis[J]. J Clin Microbiol, 2014, 52(11): 3987-3991. doi: 10.1128/JCM.01793-14
[27]	Garweg JG, de Groot-Mijnes JDF, Montoya JG. Diagnostic approach to ocular toxoplasmosis[J]. Ocul Immunol Inflamm, 2011, 19(4): 255-261. doi: 10.3109/09273948.2011.595872
[28]	Mathis T, Beccat S, Sève P, et al. Comparison of immunoblotting(IgA and IgG)and the Goldmann-Witmer coefficient for diagnosis of ocular toxoplasmosis in immunocompetent patients[J]. Br J Ophthalmol, 2018, 102(10): 1454-1458. doi: 10.1136/bjophthalmol-2017-311528
[29]	中华医学会眼科学分会眼免疫学组. 中国葡萄膜炎诊疗中眼内液检测专家共识(2020年)[J]. 中华眼科杂志, 2020, 56(9): 657-661. Doi: 10.3760/cma.j.cn112142-20200305-00141
[30]	Fawzy M, Mahmoud LA, El Gindy AE, et al. Value of estimating intraocular antibody production in diagnosis of typical and atypical lesions of ocular toxoplasmosis[J]. J Egypt Soc Parasitol, 1999, 29(3): 735-743.
[31]	Chapey E, Wallon M, Debize G, et al. Diagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay[J]. J Clin Microbiol, 2010, 48(1): 41-45. doi: 10.1128/JCM.01903-09
[32]	Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis[J]. Am J Ophthalmol, 2002, 134(1): 102-114. doi: 10.1016/s0002-9394(02)01526-x
[33]	Arruda S, Vieira BR, Garcia DM, et al. Clinical manifestations and visual outcomes associated with ocular toxoplasmosis in a Brazilian population[J]. Sci Rep, 2021, 11: 3137. doi: 10.1038/s41598-021-82830-z
[34]	Bonfioli AA, Orefice F. Toxoplasmosis[J]. Semin Ophthalmol, 2005, 20(3): 129-141. doi: 10.1080/08820530500231961
[35]	Kim SJ, Scott IU, Brown GC, et al. Interventions for Toxoplasma retinochoroiditis: a report by the American academy of ophthalmology[J]. Ophthalmology, 2013, 120(2): 371-378. doi: 10.1016/j.ophtha.2012.07.061
[36]	Pradhan E, Bhandari S, Gilbert RE, et al. Antibiotics versus no treatment for Toxoplasma retinochoroiditis[J]. Cochrane Database Syst Rev, 2016, 2016(5): CD002218. doi: 10.1002/14651858.CD002218.pub2

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed